|
2018-09-17 |
Superiority and non-inferiority: two sides of the same coin?
published
| article-journal
doi:10.1186/s13063-018-2885-z
|
|
2020-09-18 |
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
published
| stub
| v1 | CC-BY
doi:10.6084/m9.figshare.c.5125536.v1
|
|
2020-09-18 |
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
published
| stub
| CC-BY
doi:10.6084/m9.figshare.c.5125536
|
|
2019-07-12 |
The Connection between the Averted Infections Ratio and the Rate Ratio in Active-control Trials of Pre-exposure Prophylaxis Agents
published
| article-journal
doi:10.1515/scid-2019-0006
|
|
2020-09-17 |
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
published
| article-journal
doi:10.1186/s13063-020-04718-z
|
|
2020-09-18 |
Additional file 1 of Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
published
| component
| CC-BY
doi:10.6084/m9.figshare.12972225
|
|
2021 |
Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT
published
| article-journal
doi:10.3310/hta25600
|
|
2020-09-18 |
Additional file 1 of Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
published
| component
| v1 | CC-BY
doi:10.6084/m9.figshare.12972225.v1
|
|
2021 |
Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
published
| article-journal
| CC-BY
doi:10.1002/jia2.25744
|
|
2021-01-01 |
Confidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rate
published
| article-journal
| CC-BY
doi:10.1515/scid-2021-0002
|
|
2023-03-31 |
Electronic health records to capture primary outcome measures: two case studies in HIV prevention research
published
| article-journal
doi:10.1186/s13063-023-07264-6
|
|
2022-09-22 |
Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trials
unknown status
| post
doi:10.1101/2022.09.20.22276701
|